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Abstract
Background: Occasionally, breast cancer relapses more than 5 years after initial treatment, sometimes with highly
aggressive disease in such late-recurring patients. This study investigated predictors of recurrence after more than
5 years in operable breast cancer.
Methods: We retrospectively analyzed data from patients with recurrent breast cancer treated at Siriraj Hospital.
Patients were divided into those whose relapse times were longer or shorter than 5 years. Factors that predicted
late recurrence were analyzed in both the overall population and the luminal subgroup. Patterns of relapse,
changes in biomarkers, and time to disease progression after first relapse were also recorded.
Results: We included 300 women whose breast cancers recurred between 2005 and 2013, of whom 180 had
recurrence within 5 years of diagnosis and 120 later than 5 years (median time to recurrence: 45.43 months; range:
4.4–250.3 months). Tumors larger than 2 cm, lymph node metastasis, and high nuclear grade were related with
early recurrence. Estrogen receptor-positive, progesterone receptor-positive, and HER2− disease predicted late
recurrence. Almost all late-relapsing patients with luminal tumors had high estrogen receptor (ER+) titers (≥50 %)
and HER2− disease. Liver and brain were the most common early recurrence sites. Biomarkers did not significantly
change by time of recurrence.
Conclusions: ER+/PR+ and HER2− patients have higher risk of recurrence later than 5 years, especially in patients
with high ER titer and low nuclear grade. Larger and node-positive tumors had higher risk of early recurrence.
Keywords: Breast cancer, Clinicopathological, Late recurrence, Luminal breast cancer
Abbreviations: ER, Estrogen receptor; HER2, Human epidermal receptor 2; TN, Triple-negative; PR, Progesterone
receptor; ICD10, International classification of disease and related health problem 10th revision; DFS, Disease-free
survival
Background
Breast cancer, the most common cancer in women, is
highly heterogeneous with various clinical courses and
outcomes. Adjuvant systemic therapies, including chemo-
therapy, hormonal treatment, and anti-HER2 (human
epidermal receptor) agents have been proven to reduce
disease recurrence and prolong survival. Breast cancers
are classified into genomically defined subgroups, includ-
ing four major intrinsic subtypes: luminal A, luminal B,
HER2+, and triple-negative (TN) tumors. Clinical courses,
patterns of metastasis, and prognosis vary among these
subgroups. Although most relapses occur during the first
5 years after diagnosis, late recurrence has been reported,
especially in luminal breast cancer.
Unlike most solid malignancies, breast cancer may
recur 5–10 years after initial treatment. Previous studies
reported that high-bulk disease, high proliferative index,
and HER2-positive malignancies corresponded to re-
currence earlier than 10 years, whereas progesterone
receptor-positive (PR+) disease was associated with
relapse later than 10 years [1, 2]. Follow-up visits are
usually scheduled annually for patients who have had
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five disease-free years or who have completed hormonal
treatment. Some patients develop rapid and extensive
metastasis during the follow-up intervals; a few of these
patients cannot undergo chemotherapy owing to organ
dysfunction or lower performance status as a result of
widespread metastasis.
Although adjuvant chemotherapy reduces the risk of re-
currence in the first 5 years [3], its effect beyond 5 years is
unknown. Patients with estrogen receptor-positive (ER+)
breast cancer benefit from adjuvant tamoxifen, with the
greatest benefit in the first 4 years [4] and an additional
carry-over reduction of recurrence risk for more than
5 years. Use of tamoxifen extended to 10 years in women
with early-stage breast cancer reportedly reduces the risk
of late recurrence [5]. Despite the substantial benefit of
the 10-year tamoxifen regimen, higher incidence of tox-
icity, including endometrium cancer and thromboembol-
ism, has also been shown. To improve risks and benefits,
patients with high chances of late relapse might be better
candidates for such long-term treatment.
Table 1 Patients’ characteristics by time to diagnosis of breast cancer recurrence
Time to recurrence Total (n = 300) p
<5 years (n = 180) ≥5 years (n = 120)
Mean age, years (SD) 48.45 (10.59) 49.17 (10.61) 300 0.562
Menopausal status Pre/peri-menopause 138 (76.6) 83 (69.1) 221 0.628
Postmenopause 42 (23.4) 37 (30.9) 79
T stage ≤2 cm 40 (22.2) 51 (42.5) 91 <0.001
>2 cm 140 (77.8) 69 (57.5) 209
N stage Node-negative 53 (29.4) 69 (56.6) 122 <0.001
Node + 1-3 nodes 56 (31.1) 36 (30) 92
Node + 4-9 nodes 39 (21.7) 12 (10) 51
Node+ ≥ 10 nodes 32 (17.8) 3 (2.5) 35
N stage Node-negative 53 (29.4) 69 (56.6) 121 <0.001
Node-positive 127 (70.6) 51 (43.4) 179
Grade (n = 262) 1 13 (7.6) 19 (20.6) 32 0.002
2 103 (60.5) 56 (60.8) 159
3 54 (31.9) 17 (18.6) 71
LVI (n = 262) Yes 108 (63.9) 43 (46.2) 151 0.006
No 61 (36.1) 50 (53.8) 111
ER Positive 101 (56.1) 104 (86.6) 205 0.001
Negative 79 (43.9) 16 (13.4) 95
PR Positive 76 (42.2) 95 (79.1) 171 0.001
Negative 104 (57.8) 25 (20.9) 129
HER2 Positive 60 (33.3) 5 (4.1) 65 0.001
Negative 120 (66.7) 115 (95.9) 235
Subtypes Luminal A/B/HER2− 76 (42.2) 102 (85.0) 178 0.001
Triple-negative 44 (24.4) 13 (10.8) 57
HER2 35 (19.4) 2 (1.6) 37
ER+ or PR+ and HER2+ 25 (14.0) 3 (2.6) 28
Surgery (n = 293) Mastectomy 163 (90.5) 106 (88.3) 269 0.31
Breast-conserving 12 (6.7) 12 (10) 24
Adjuvant systemic treatment None 8 (4.4) 4 (3.3) 12 0.001
Chemotherapy 81 (45.0) 20 (16.6) 101
Endocrine therapy 17 (9.4) 35 (29.1) 52
Chemo-endocrine 74 (41.2) 61 (51.0) 135
Adjuvant RT Yes 108 (60.0) 47 (39.1) 155 0.073
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The objective of this study was to identify predictors
of relapse later than 5 years in early breast cancer.
Secondary objectives were identification of predictors of
late recurrence specifically in luminal breast cancer,
patterns of recurrence, and changes in biomarkers by
the time of recurrence. Predicting patients with high
chances of late relapse may modify individual follow-up
schedules and individualize long-term hormonal treat-
ment in the right patients.
Methods
All patients who had histologically confirmed breast can-
cers that recurred after initial treatment were retrospect-
ively reviewed. Patients with incomplete biomarker data
were excluded. Data from all patients with recurrent
breast cancer were recorded, including demographic,
initial stage and tumor biomarkers, date and site of recur-
rence, any change in biomarkers, and time to progression
after first relapse.
Tumors were defined as positive for ER or PR if more
than 1 % of cells expressed ER or PR (respectively) [6].
Tumors were considered HER2+ if they scored 3+ by
immunohistochemistry; or if the ratio of HER2-neu and
centromere of 17th chromosome was greater than 2 [7].
For our secondary objectives regarding predictors of
late relapse in luminal tumors, we decided to use ER
titer as a possible predictive marker. Low ER titer was
defined as less than 50 % of tumor cells expressing ER
immunohistochemically [8].
All enrolled patients were divided into two groups;
those whose relapses were within the first 5 years, and
later than 5 years from initial treatment, were respect-
ively grouped as the early recurrence and late recurrence
groups. Clinical, pathological, and biomarker data were
analyzed for factors that predicted late recurrence in all
patients, and in those with luminal tumors. Patterns of
relapse and changes of biomarkers over time were also
evaluated. The study was approved by Siriraj Institu-
tional Review Board (Protocol number 204/2557(EC1)).
Statistical analysis
Associations between clinicopathological parameters,
immunohistological markers, and late recurrence were
assessed using the chi-square and Fisher exact test.
Multivariate analysis included only those variables that
were positive in univariate analysis and were assessed
using multiple binary logistic regression analysis. Also,
binary logistic regression was used to evaluate patterns of
metastasis in different tumor subtypes. p values were two-
sided; all confidence intervals were at 95 %. Survival curves
were estimated using Kaplan–Meier curves. Analyses were
performed using SPSS version 20. This study was
approved by the Siriraj Institution Review Board.
Results
We initially found 554 breast cancer patients who suf-
fered relapses during 2005–2013 using the International
Classification of Disease and related health problem
10th revision (ICD10) codes for metastatic breast cancer.
After excluding patients with metastatic disease at the
first diagnosis, who had incomplete data, or who had re-
fused surgery, 300 patients were eligible for analysis.
Their median age was 48 years old. Most of the patients
(75 %) were premenopausal at the time of first diagnosis.
Their median time to first recurrence was 45.4 months
(range: 4.4–250 months). For all patients whose disease
had recurred, 78 and 90 % developed recurrence within 10
and 15 years, respectively. Almost all patients received
adjuvant systemic treatment and radiotherapy as their
physician recommended; only 4 % rejected at least one rec-
ommended therapy. Of patients for whom chemotherapy
was indicated, 60 % received anthracycline-based chemo-
therapy and 19 % had combined methotrexate, 5FU, and
oral cyclophosphamide. Previously, most patients had re-
ceived tamoxifen as an adjuvant hormonal therapy.
We divided patients into two groups, early recurrence
(within 5 years after diagnosis; n = 180; 60 %) and late
recurrence (later than 5 years; n = 120; 40 %). There was
no difference in both early and late recurrence rates
among patients who underwent mastectomy and breast-
conserving surgery. Among node-positive patients, 70 %
were in the early group and 43 % were in the late group
(p < 0.001). Patients with tumors larger than 2 cm expe-
rienced more frequent early recurrence (78 % early
Table 2 Univariate and multivariate analyses of factors
correlated with late recurrence (≥5 years)
Factors Univariate analysis Multivariate analysis
RR/CI p RR/CI p
T stage ≤2 cm 2.59/1.57–4.28 <0.001 2.09/1.09–3.99 0.026
>2 cm 1 1
N stage − 3.24/2.0–5.26 0.137
+ 1
Grade 1 1 1
2 0.39/0.18–0.85 0.017 0.39/0.15–0.97 0.043
3 0.24/0.1–0.58 0.001 0.46/0.17–1.3 0.142
LVI + 0.49/0.29–0.81 0.006 0.82/0.44–1.55 0.546
− 1 1
ER + 5.08/2.78–9.29 <0.001 3.25/1.1–9.6 0.033
− 1
PR + 5.20/3.06–8.84 <0.001 1.86/0.75–4.62 0.184
− 1 1
HER2 + 0.09/2.35–29.3 <0.001 0.12/0.03–0.43 0.001
− 1 1
RR relative risk, CI 95 % confidence interval, LVI lymphovascular invasion
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group vs 57 % later group). Subtypes of breast cancer
also predicted recurrence time. Most of the late group
had luminal tumors (85 %) followed by TN tumor
(11 %). Among 65 HER2+ patients, only 5 (4.2 %) experi-
enced late recurrence, as did only 1.6 % of patients with
ER−/PR−/HER2+ tumors (Table 1).
Most patients with tumors larger than 2 cm or lymph
node metastasis relapsed early, while higher proportion
of patients with small tumors or negative lymph nodes
were found among patients who experienced late recur-
rence (Table 2). In multivariate analysis, factors that
predicted late recurrence were ER+, PR+ status, and
Table 4 Univariate and multivariate analyses of recurrence later than 5 years in patients with luminal tumors
Factors Category Later than 5 years Univariate analysis Multivariate analysis
/total n RR/CI p RR/CI p
T stage ≤2 cm 45/65 3.04/1.63–5.67 <0.001 3.96/1.66–9.43 0.002
>2 cm 60/141 1 1
N stage Node− 60/89 3.31/1.86–5.91 <0.001 3.47/1.51–7.99 0.003
Node+ 45/117 1 1
Grade 1 15/23 1 1
2 53/115 0.46/0.18–1.16 0.099 0.15/0.04–0.62 0.008
3 14/41 0.28/0.10–0.81 0.019 0.23/0.05–1.05 0.057
ER titer High≥ 50 % 72/139 8.06/1.78–36.57 0.007 10.4/1.88–57.5 0.007
Low < 50 % 2/17 1 1
ER− or PR− Yes 101/176 8.75/2.93–26.15 <0.001 2.95/0.12–74.6 0.511
No 4/30 1 1
HER2 Positive 3/28 0.09/0.03–0.31 <0.001 0.44/0.01–16.9 0.655
Negative 102/178 1 1
RR relative risk, CI 95 % confidence interval
Table 3 Patient characteristics by time to diagnosis of recurrence of breast cancer in luminal subgroup
Time to recurrence Total
(n = 206)
p
<5 years (n = 101) ≥5 years (n = 105)
Mean age, years (SD) 49.17 (10.5) 48.45 (10.6) 206 0.562
Menopausal status Pre/peri-menopause 74 (73.2) 71 (67.6) 145 0.377
Postmenopause 27 (26.8) 34 (32.4) 61
T stage ≤2 cm 19 (18.9) 42 (40.0) 61 0.001
>2 cm 82 (81.1) 63 (60.0) 145
N stage Node-negative 29 (28.7) 59 (56.2) 88 <0.001
Node-positive 72 (71.3) 46 (43.8) 118
Grade (n = 174) 1 9 (9.4) 15 (18.9) 24 0.019
2 59 (62.1) 51 (64.5) 110
3 27 (28.5) 13 (16.6) 40
Lymphovascular invasion (n = 176) Yes 59 (62.1) 42 (51.8) 101 0.172
No 36 (37.9) 39 (48.2) 75
ER titer (n = 156) High (≥50 %) 67 (81.7) 72 (97.2) 139 0.002
Low (<50 %) 15 (18.3) 2 (2.8) 17
ER− or PR− 26 (25.7) 4 (3.8) 30 <0.001
HER2+ 25 (24.7) 3 (2.8) 28 <0.001
Adjuvant therapy None 4 (3.9) 2 (1.9) 6 0.047
Chemotherapy 7 (6.9) 7 (6.6) 14
Endocrine therapy 17 (16.8) 35 (33.3) 52
Chemo-endocrine 73 (72.4) 61 (58.2) 154
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HER2−status, whereas HER2+ status predicted early
relapse (Table 2).
Because luminal tumors had a substantial chance
of late recurrence, we investigated factors that pre-
dict late relapse in this specific population. Among
the enrolled 300 patients, 206 (68.7 %) had ER+ and/
or PR+ tumors. Of 206 patients with luminal tumor,
105 (50.9 %) experienced late recurrence; as with the
overall population, early recurrence occurred in lu-
minal tumor patients with larger tumor, positive
lymph nodes, and HER2 amplification (Tables 3 and
4). Two out of 74 late-relapse patients (2.8 %) had low
ER titers, and 15 out of 92 patients with early relapse
(18 %) had low ER (p = 0.002). Patients with low ER
titers or whose tumors were ER− or PR− had signifi-
cantly less late relapse (Table 3). Multivariate analysis
associated highly positive ER intensity with late
recurrence (Table 4).
The different breast cancer subtypes showed different
times to disease progression. As expected, the luminal/
HER2− subgroup had the longest disease-free survival
(DFS; median DFS: 65.95 months), whereas patients with
TN or ER−/HER2+ disease had worse prognoses (median
DFS: 23.7 and 24.4 months, respectively; Fig. 1). How-
ever, at that time, 92.2 % of HER2+ patients received no
adjuvant trastuzumab owing to reimbursement issues
and financial constraints.
Liver and brain were the most common metastasis
sites for patients with early relapse. However, lung or
soft tissue and bone metastasis occurred throughout
the follow-up period. Patients with locoregional
recurrence as first relapse site experienced longer DFS
(median: 82.55 months; range: 7.17–234.9 months)
compared with those with distant metastasis (median
DFS: 42.58 months; range: 4.40–250.27 months). In the
overall population, metastasis to the central nervous
system was largely found in patients with TN and
HER2+ cancers. Luminal HER2− tumors were predom-
inantly metastasized to the bone and were less likely to
spread to the liver at first relapse (Tables 5 and 6).
Patterns of relapse did not significantly differ between
luminal patients who relapsed late or early (Table 7).
The late-relapse group had longer median time to
disease progression (15.16 months) than did the early
group (8.16 months; p = 0.008) (Fig. 2).
Fig. 1 Cumulative incidence of first relapse of breast cancer by breast cancer subtype
Table 5 Metastasis patterns according to the time to diagnosis
of breast cancer recurrence







Pulmonary metastasis 132 (73.3) 91 (75.8) 223 0.102
Bone metastasis 82 (45.5) 58 (48) 140 1.051
Brain metastasis 22 (12.2) 4 (3.3) 26 0.007
Liver metastasis 57 (31.6) 20 (16.6) 77 0.004
LN metastasis 38 (21.1) 29 (24.1) 67 0.534
Skin metastasis 32 (17.7) 22 (18.3) 54 0.902
Locoregional recurrence 10 (5.0) 16 (8.0) 26 0.019
Distant metastasis 170 (94.4) 104 (86.6) 274 0.088
Multiple site metastasis 132 (73.3) 76 (63.3) 208 0.066
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Eighty of the 300 patients were re-biopsied at the time
of recurrence. Most (79 %) had biomarkers similar
to those seen at their initial diagnoses. Discordant
biomarkers were infrequent and did not significantly dif-
fer by relapse time (Table 8).
Discussion
As with most solid cancers, breast cancer relapse rates
are highest in the first 5 years following initial treatment
and decline to a steady state after 7–8 years. Late relapse
of breast cancer is occasionally found after DFS of 5–
10 years. Breast cancer patients who had high disease
bulk (such as large tumors or positive lymph nodes) gen-
erally had higher chances of both early and late recur-
rence [1]. A previous study showed that recurrence that
occurred later than 10 years was associated with positive
lymph node or PR+ disease [2].
Our study confirmed that tumor size and regional
lymph node involvement were predictive of early recur-
rence. In addition, biomarkers were stronger predictors
of early or late recurrence. HER2+ status predicted re-
currence within 5 years; only five HER2+ patients (4 %)
were in the late group, and three of these five also had
positive hormone receptors. Because TN breast cancer is
known to be an especially aggressive subtype, our study
showed cancers of this subtype made up 10 % of the late
group, compared with 24 % of the early group. These
patterns have implications for follow-up scheduling in
patients whose DFS has been longer than 5 years; HER2+
patients can be set for annual visits, whereas ER+ patients
(especially those who had high ER titer) might need more
frequent follow-up visits because the risk of recurrence is
still retained.
Patients with hormone receptor-positive breast cancer
remain at risk of recurrence for as long as they survive.
For that reason, many investigators have explored the
benefit of extended therapy beyond the standard treat-
ment of 5 years. Recently, several studies showed that
extended tamoxifen reduces late recurrence risk by one
third compared with no further hormonal therapy
beyond 5 years [5, 9]. Extended use of aromatase inhibi-
tors has also been shown to reduce the risk of late
relapse by nearly 50 % compared with no further treat-
ment [10, 11]. However, prolonged endocrine therapy
leads to adverse events (such as hot flashes, sexual dys-
function, uterine bleeding, or osteoporosis) in approxi-
mately half of patients who take it. Therefore, treating
only patients with a clear chance of recurrence but not
those unlikely to develop late recurrence is a reasonable
practice. The question is: Which patient has risk of
late relapse and will benefit from extended hormonal
therapy?
We therefore explored more patients with luminal
tumors. Identifying patients with high risk of late
relapse and who may benefit from extended hormo-
nal therapy for up to 10 years could aid in treatment
decisions. In luminal tumors, titers of ER and HER2
predicted late relapse. Patients with ER titers <50 %
or concomitant HER2+ disease experienced signifi-
cantly lower rates of late recurrence. Therefore,
benefits of extended hormonal treatment in these
patients might not outweigh the risk of treatment.
Given that coexpression of ER and PR were related
to late recurrence compared with patients who had
only ER or PR, our findings support greater benefit
of extended letrozole treatment in patients who had
ER+/PR+ tumors, as shown in subsequent analysis of
MA17 [12].
Table 6 Relative risk for site of first recurrence by breast cancer subtype in 300 women
Site TNBC (n = 57) HER2 (n = 37) ER/PR/HER2 (n = 28) ER/PR (n = 178)
RR/CI p RR/CI p RR/CI p RR/CI p
Lung 0.959/0.49–1.84 0.901 0.655/0.36–1.19 0.166 0.495/0.22–1.11 0.083 1.399/0.82–2.35 0.207
Bone 0.554/0.30–1.00 0.052 0.708/0.40–0.23 0.223 1.159/0.53–2.52 0.710 1.849/1.15–2.95 0.010
Brain 2.493/1.04–5.92 0.034 2.489/1.07–5.78 0.030 3.436/1.25–9.44 0.024 0.222/0.09–0.54 <0.001
Liver 1.439/0.76–2.70 0.256 4.897/2.71–8.82 <0.001 1.70/0.74–3.86 0.201 0.220/0.12–0.38 <0.001
LN 1.641/0.85–3.13 0.131 2.160/1.17–3.96 0.012 1.748/0.75–4.06 0.191 0.397/0.22–0.69 0.001
Skin 1.112/0.53–2.32 0.777 0.577/0.25–1.29 0.177 0.740/0.24–2.22 0.551 1.327/0.71–2.45 0.365
CI 95 % confidence interval, RR relative risk, TNBC triple-negative breast cancer
Table 7 Metastasis patterns in patients with luminal subtypes
according to the time to diagnosis of breast cancer recurrence
Site of first
recurrence







Pulmonary metastasis 71 (70.2) 83 (79.0) 154 0.150
Bone metastasis 58 (57.4) 50 (47.6) 108 0.160
Brain metastasis 9 (8.9) 4 (3.8) 13 0.134
Liver metastasis 20 (19.8) 15 (14.2) 35 0.294
LN metastasis 13 (12.8) 24 (22.8) 37 0.062
Skin metastasis 20 (19.8) 19 (18.0) 39 0.756
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Recently, studies using multi-parameter assays, for
example the 12-gene EndoPredict, Breast Cancer
Index (BCI), or 50 gene PAM50 ROR, investigated the
risk of late recurrence [13, 14]. These molecular
assays can separate patients with low risk of develop-
ing recurrence at 5–10 years or 10–15 years [15].
Among these parameters, PAM50 ROR was the stron-
gest molecular prognostic factor for late recurrence
and possibly predicted who could benefit most from
extended hormonal treatment [1]. However, these data
were exploratory, and validation of their applicability
to specific subgroups is needed. These multi-
parameter assays are also limited by availability and
cost. Clinicopathological parameters remain the key
to clinical decision-making in our practice.
As for patterns of metastasis, patients who relapsed
early tended to have liver and brain metastasis, whereas
metastasis to the bone occurred independently of the
period of time to relapse. For the course of disease, Fig. 2
shows slower disease progression in the late group.
These can be explained by more indolent biology in
patients with late relapse.
The main limitation of our study was its retrospect-
ive design based on clinicopathological data. Some past
adjuvant therapies also do not represent current stand-
ard practices; for instance, trastuzumab was rarely
used in high-risk HER2+ breast cancer patients because
of availability and reimbursement issues. In addition,
some parameters such as Ki67 have not been used gen-
erally at the time of breast cancer diagnosis in our
institution.
Conclusions
Larger and node-positive tumors associate with greater
chances of early recurrence. Factors that predict late
recurrence are luminal tumors, especially with concomi-
tant PR-positive status, high ER titer, small tumor, nega-
tive lymph node, low grade, and HER2− disease.
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Fig. 2 Progression-free survival after first relapse categorized by early or late recurrence (months)
Table 8 Discordance of hormonal receptor and HER2 status
between primary and metastatic samples (only in patients with
rebiopsies and with diagnoses confirmed by pathologist; n = 80)





No change ER status 36 36
ER change Pos→ neg 2 2
Neg→ pos 2 2
No change PR status 35 37
PR change Pos→ neg 2 2
Neg→ pos 3 1
No change HER2 status 35 38
HER2 change Pos→ neg 1 0
Neg→ pos 4 2
Changes were seen in 17 patients (some patients had more than 1
biomarker changed)
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